Drug Profile
Research programme: AAV-based gene therapies - Neuralgene
Alternative Names: PRCN 226; PRCN 408; PRCN 829Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Neuralgene
- Developer Neuralgene; Precision StemCell
- Class Gene therapies
- Mechanism of Action Complement factor H modulators; Complement system protein inhibitors; Gene modulators; Growth factor receptor modulators; Neurogenesis stimulants; TDP-43 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Macular degeneration; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Colombia
- 28 Sep 2022 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in Colombia
- 28 Sep 2022 No recent reports of development identified for research development in Macular-degeneration in Colombia